vonoprazan 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
proton pump inhibitors, not dependent on acid activation 4993 881681-00-1

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • vonoprazan
  • vonoprazan fumarate
  • takecab
  • TAK-438
Vonoprazan is a potassium-competitive proton pump blocker which was approved in Japan for the treatment of gastroduodenal ulcer. FDA approved a co-packaged combination of vonoprazan and antibiotics (amoxicillin and clarithromycin) to eradicate Helicobacter pyroli. Its potential to combat cytokine release syndrome (CRS) in patients with severely ill COVID-19 was investigated. Accordingly, it is recommended to use tocilizumabin combination with dexamethasone (or another corticosteroid at an equivalent dose) in certain hospitalized patients who are exhibiting rapid respiratory decompensation caused by COVID-19.
  • Molecular weight: 345.39
  • Formula: C17H16FN3O2S
  • CLOGP: 2.54
  • LIPINSKI: 0
  • HAC: 5
  • HDO: 1
  • TPSA: 63.99
  • ALOGS: -3.85
  • ROTB: 4
  • Status: ONP
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

None

ADMET properties:

None

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
kinase-safety-class ACVR2B,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK5,CDK9,EGFR,EIF2AK3,ERBB2,GRK2,ITK,MAPK10,MAPK7,MAPKAPK2,MET,NTRK2,PDK1,PDK2,PDK4,PIK3CB,PRKDC,TEK,TGFBR1 25
kinase-selectivity-class AXL,BRAF,CDK9,EPHB4,ERBB2,GRK2,MAPK7,SIK2 8
pfas-class PFAS structural alert (1 = True, 0 = False) 0

Approvals:

DateAgencyCompanyOrphan
Dec. 26, 2014 PMDA
Nov. 1, 2023 FDA PHATHOM

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Hepatic function abnormal 175.91 22.02 80 6628 46208 90575531
Renal impairment 105.15 22.02 76 6632 105345 90516394
Interstitial lung disease 94.77 22.02 63 6645 76342 90545397
Platelet count decreased 91.64 22.02 78 6630 136891 90484848
Cerebral infarction 85.57 22.02 41 6667 26555 90595184
Cardiac failure 74.53 22.02 63 6645 109433 90512306
Decreased appetite 73.60 22.02 113 6595 376427 90245312
Anaemia 70.52 22.02 107 6601 352695 90269044
Neutrophil count decreased 63.25 22.02 48 6660 71484 90550255
Gastric polyps 57.49 22.02 19 6689 4653 90617086
Fulminant type 1 diabetes mellitus 55.96 22.02 13 6695 865 90620874
Drug eruption 50.76 22.02 32 6676 35375 90586364
Enterocolitis 49.06 22.02 21 6687 10469 90611270
Pneumonia bacterial 48.19 22.02 22 6686 12768 90608971
Altered state of consciousness 46.46 22.02 29 6679 31503 90590236
White blood cell count decreased 45.71 22.02 59 6649 167050 90454689
Gastric cancer 40.53 22.02 15 6693 5121 90616618
Disseminated intravascular coagulation 40.02 22.02 23 6685 21515 90600224
Hypergastrinaemia 38.57 22.02 7 6701 134 90621605
Cytokine release syndrome 36.91 22.02 24 6684 27949 90593790
Aplasia pure red cell 36.73 22.02 14 6694 5180 90616559
Gastrointestinal polyp haemorrhage 36.22 22.02 8 6700 424 90621315
Marasmus 36.03 22.02 9 6699 814 90620925
Pneumonia aspiration 35.13 22.02 27 6681 40913 90580826
Pulmonary toxicity 34.73 22.02 17 6691 11514 90610225
Cardiac failure acute 34.18 22.02 17 6691 11912 90609827
Fatigue 33.88 22.02 22 6686 1154001 89467738
Enterocolitis haemorrhagic 33.70 22.02 10 6698 1722 90620017
Cardiac failure chronic 32.12 22.02 13 6695 5633 90616106
Focal peritonitis 31.58 22.02 5 6703 40 90621699
Blood pressure decreased 31.47 22.02 33 6675 74862 90546877
Pneumocystis jirovecii pneumonia 29.64 22.02 19 6689 21597 90600142
Dehydration 29.30 22.02 52 6656 194395 90427344
Pyrexia 29.20 22.02 111 6597 660374 89961365
Hypocalcaemia 28.01 22.02 24 6684 42344 90579395
Pain 27.87 22.02 20 6688 996321 89625418
Diabetic ketoacidosis 27.54 22.02 19 6689 24388 90597351
Hypomagnesaemia 27.36 22.02 22 6686 35566 90586173
Liver disorder 27.34 22.02 39 6669 121230 90500509
Aortic dissection 26.45 22.02 9 6699 2408 90619331
Erythema multiforme 25.24 22.02 14 6694 12232 90609507
Hypothyroidism 25.21 22.02 25 6683 53102 90568637
Herpes zoster 25.20 22.02 33 6675 94611 90527128
Drug-induced liver injury 24.84 22.02 32 6676 90286 90531453
Hypoalbuminaemia 24.37 22.02 15 6693 15882 90605857
COVID-19 23.95 22.02 44 6664 168799 90452940
Cholangitis 22.87 22.02 11 6697 7171 90614568
Familial mediterranean fever 22.60 22.02 4 6704 66 90621673
Femur fracture 22.45 22.02 22 6686 46060 90575679
Nephrogenic anaemia 22.43 22.02 8 6700 2458 90619281

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Interstitial lung disease 234.06 19.86 160 8043 78302 42534830
Hepatic function abnormal 99.29 19.86 81 8122 51486 42561646
Immune-mediated enterocolitis 84.04 19.86 34 8169 5643 42607489
Cerebral infarction 82.04 19.86 59 8144 31110 42582022
Pulmonary toxicity 67.27 19.86 33 8170 8622 42604510
Decreased appetite 66.71 19.86 127 8076 193010 42420122
Renal impairment 65.98 19.86 93 8110 110135 42502997
Cardiac failure 63.72 19.86 90 8113 106766 42506366
Pneumonia aspiration 61.35 19.86 61 8142 50017 42563115
Cholangitis 57.83 19.86 32 8171 10695 42602437
Immune-mediated hepatic disorder 54.94 19.86 20 8183 2494 42610638
Adrenal insufficiency 54.83 19.86 38 8165 18886 42594246
Pneumonia bacterial 53.83 19.86 35 8168 15657 42597475
Liver disorder 53.63 19.86 51 8152 39593 42573539
Colitis microscopic 47.18 19.86 19 8184 3114 42610018
Hypergastrinaemia 44.43 19.86 10 8193 216 42612916
Neutrophil count decreased 40.12 19.86 55 8148 63360 42549772
Gastric cancer 38.32 19.86 21 8182 6882 42606250
Adrenocorticotropic hormone deficiency 37.95 19.86 13 8190 1357 42611775
Cholangitis acute 35.87 19.86 12 8191 1165 42611967
Immune-mediated lung disease 35.49 19.86 16 8187 3457 42609675
Blood gastrin increased 33.39 19.86 6 8197 38 42613094
Asthenia 32.87 19.86 7 8196 280786 42332346
Malignant neoplasm progression 32.16 19.86 67 8136 108333 42504799
Radiation pneumonitis 31.53 19.86 14 8189 2919 42610213
Cytokine release syndrome 30.26 19.86 40 8163 44487 42568645
Cholangitis sclerosing 30.25 19.86 12 8191 1890 42611242
Drug-induced liver injury 30.14 19.86 37 8166 38236 42574896
Disseminated intravascular coagulation 29.96 19.86 30 8173 24764 42588368
Tumour haemorrhage 28.65 19.86 14 8189 3624 42609508
Non-small cell lung cancer 27.25 19.86 15 8188 4959 42608173
C-reactive protein increased 27.23 19.86 46 8157 63514 42549618
Immune-mediated cholangitis 27.02 19.86 8 8195 521 42612611
Fulminant type 1 diabetes mellitus 26.60 19.86 10 8193 1364 42611768
Enterocolitis 26.57 19.86 19 8184 9910 42603222
Altered state of consciousness 25.85 19.86 30 8173 29229 42583903
Drug eruption 24.42 19.86 26 8177 23049 42590083
Platelet count decreased 24.33 19.86 70 8133 138511 42474621
Physical deconditioning 24.32 19.86 11 8192 2394 42610738
Drug ineffective 23.06 19.86 55 8148 630142 41982990
Marasmus 22.85 19.86 8 8195 891 42612241
Renal disorder 22.79 19.86 28 8175 28952 42584180
Hepatocellular carcinoma 22.66 19.86 16 8187 8178 42604954
Immune-mediated hepatitis 22.39 19.86 12 8191 3762 42609370
Pleural effusion 22.04 19.86 54 8149 97112 42516020
Dyslalia 21.46 19.86 7 8196 628 42612504
Cardiac failure acute 21.26 19.86 19 8184 13614 42599518
Thyroiditis 21.22 19.86 11 8192 3225 42609907
Thrombophlebitis migrans 20.68 19.86 6 8197 364 42612768
Fatigue 20.23 19.86 33 8170 435608 42177524

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Interstitial lung disease 327.46 19.20 215 14824 139119 110435141
Hepatic function abnormal 262.83 19.20 159 14880 89136 110485124
Renal impairment 162.97 19.20 162 14877 188283 110385977
Cerebral infarction 162.01 19.20 96 14943 51742 110522518
Cardiac failure 132.92 19.20 145 14894 187481 110386779
Decreased appetite 127.30 19.20 230 14809 475616 110098644
Pulmonary toxicity 104.04 19.20 50 14989 17696 110556564
Platelet count decreased 102.79 19.20 141 14898 230302 110343958
Pneumonia bacterial 101.80 19.20 56 14983 26205 110548055
Pneumonia aspiration 101.72 19.20 86 14953 81147 110493113
Neutrophil count decreased 100.83 19.20 102 14937 120839 110453421
Immune-mediated enterocolitis 99.34 19.20 41 14998 10144 110564116
Cholangitis 86.69 19.20 43 14996 16292 110557968
Immune-mediated hepatic disorder 72.40 19.20 26 15013 4424 110569836
Enterocolitis 72.32 19.20 40 14999 18909 110555351
Hypergastrinaemia 71.10 19.20 15 15024 341 110573919
Drug eruption 69.62 19.20 58 14981 53601 110520659
Altered state of consciousness 68.03 19.20 59 14980 57567 110516693
Cytokine release syndrome 67.34 19.20 64 14975 70242 110504018
Disseminated intravascular coagulation 67.21 19.20 51 14988 41235 110533025
Fulminant type 1 diabetes mellitus 67.11 19.20 21 15018 2342 110571918
Gastric cancer 64.47 19.20 31 15008 10977 110563283
Liver disorder 63.31 19.20 87 14952 142156 110432104
Anaemia 62.99 19.20 190 14849 546896 110027364
Malignant neoplasm progression 60.65 19.20 95 14944 174472 110399788
Fatigue 59.70 19.20 47 14992 1215911 109358349
Adrenal insufficiency 59.56 19.20 48 14991 42342 110531918
Pain 57.73 19.20 29 15010 954926 109619334
Gastric polyps 56.47 19.20 23 15016 5500 110568760
Colitis microscopic 53.11 19.20 29 15010 13365 110560895
White blood cell count decreased 52.60 19.20 104 14935 229286 110344974
Marasmus 52.12 19.20 16 15023 1675 110572585
Cardiac failure acute 48.87 19.20 34 15005 24044 110550216
Radiation pneumonitis 46.75 19.20 19 15020 4517 110569743
Blood gastrin increased 46.35 19.20 8 15031 58 110574202
Joint swelling 45.48 19.20 4 15035 442841 110131419
Blood pressure decreased 44.72 19.20 66 14973 115025 110459235
Asthenia 44.57 19.20 19 15020 688980 109885280
Drug hypersensitivity 44.29 19.20 5 15034 454085 110120175
Adrenocorticotropic hormone deficiency 44.15 19.20 15 15024 2167 110572093
Physical deconditioning 44.10 19.20 17 15022 3520 110570740
Drug-induced liver injury 44.01 19.20 67 14972 120000 110454260
Immune-mediated lung disease 43.89 19.20 19 15020 5284 110568976
Drug ineffective 43.22 19.20 89 14950 1520451 109053809
Hypothyroidism 42.50 19.20 51 14988 72848 110501412
Aplasia pure red cell 41.51 19.20 22 15017 9556 110564704
Peripheral swelling 40.55 19.20 4 15035 404030 110170230
Gastrointestinal polyp haemorrhage 40.10 19.20 11 15028 774 110573486
Cardiac failure chronic 39.04 19.20 24 15015 13787 110560473
Immune-mediated cholangitis 38.80 19.20 11 15028 873 110573387
Pyrexia 38.73 19.20 231 14808 898034 109676226
Cholangitis acute 38.11 19.20 13 15026 1900 110572360
Tumour haemorrhage 37.63 19.20 17 15022 5228 110569032
Pneumocystis jirovecii pneumonia 37.33 19.20 37 15002 42698 110531562
Non-small cell lung cancer 36.59 19.20 19 15020 7916 110566344
COVID-19 35.89 19.20 93 14946 244967 110329293
Febrile neutropenia 35.41 19.20 109 14930 316658 110257602
Hypoalbuminaemia 34.86 19.20 30 15009 28944 110545316
Hypomagnesaemia 34.81 19.20 42 14997 60328 110513932
Enterocolitis haemorrhagic 34.20 19.20 13 15026 2591 110571669
Swelling 33.88 19.20 4 15035 351037 110223223
Pleural effusion 33.06 19.20 74 14965 177635 110396625
Hepatocellular carcinoma 32.69 19.20 19 15020 9861 110564399
Dehydration 32.00 19.20 97 14942 279414 110294846
Melaena 32.00 19.20 43 14996 68714 110505546
Anxiety 30.79 19.20 5 15034 345073 110229187
Ascites 30.13 19.20 49 14990 92759 110481501
Erythema multiforme 29.86 19.20 24 15015 21073 110553187
Aortic dissection 29.21 19.20 14 15025 4919 110569341
KL-6 increased 28.67 19.20 7 15032 310 110573950
Vanishing bile duct syndrome 28.36 19.20 12 15027 3156 110571104
Focal peritonitis 28.11 19.20 5 15034 44 110574216
Immune-mediated hepatitis 27.91 19.20 15 15024 6696 110567564
Hypopituitarism 27.65 19.20 13 15026 4377 110569883
Rheumatoid arthritis 27.51 19.20 4 15035 299609 110274651
Oesophageal candidiasis 27.50 19.20 18 15021 11516 110562744
Immune-mediated myocarditis 27.22 19.20 12 15027 3486 110570774
Paraesthesia 27.06 19.20 3 15036 276518 110297742
Cholangitis sclerosing 26.94 19.20 12 15027 3570 110570690
Nephrotic syndrome 26.83 19.20 19 15020 13812 110560448
Gastrointestinal perforation 26.43 19.20 15 15024 7441 110566819
Bile duct stone 26.00 19.20 14 15025 6275 110567985
Diabetic ketoacidosis 25.46 19.20 30 15009 42028 110532232
Thyroiditis 25.42 19.20 14 15025 6559 110567701
Musculoskeletal stiffness 25.08 19.20 4 15035 279818 110294442
Hypersensitivity 24.75 19.20 12 15027 403986 110170274
Cerebellar haemorrhage 24.74 19.20 11 15028 3260 110571000
Hypocalcaemia 24.68 19.20 37 15002 65329 110508931
Renal disorder 24.65 19.20 32 15007 49447 110524813
Systemic lupus erythematosus 24.29 19.20 3 15036 254335 110319925
Spinal compression fracture 24.09 19.20 20 15019 18372 110555888
Organising pneumonia 24.07 19.20 18 15021 14225 110560035
Shunt occlusion 24.00 19.20 9 15030 1728 110572532
Hepatic encephalopathy 23.82 19.20 24 15015 28232 110546028
Type 1 diabetes mellitus 23.75 19.20 15 15024 9032 110565228
Pain in extremity 23.59 19.20 19 15020 487099 110087161
Hyperkalaemia 23.54 19.20 55 14984 135741 110438519
Gastric ulcer 23.43 19.20 28 15011 39799 110534461
Compression fracture 23.37 19.20 15 15024 9284 110564976
Immune-mediated gastritis 23.28 19.20 6 15033 332 110573928
Gastric mucosal hypertrophy 23.26 19.20 6 15033 333 110573927
Sinusitis 22.95 19.20 6 15033 296682 110277578
Diarrhoea 22.93 19.20 246 14793 1139259 109435001
Thrombophlebitis migrans 22.49 19.20 7 15032 767 110573493
Dyslalia 22.11 19.20 8 15031 1389 110572871
Dyspnoea 22.09 19.20 77 14962 1106795 109467465
Alopecia 22.09 19.20 11 15028 364742 110209518
Maternal exposure during pregnancy 22.06 19.20 4 15035 254879 110319381
Pneumonia 21.87 19.20 198 14841 876516 109697744
Cholecystitis 21.85 19.20 22 15017 25860 110548400
Blood corticotrophin decreased 21.84 19.20 7 15032 843 110573417
Toxicity to various agents 21.74 19.20 20 15019 480535 110093725
COVID-19 pneumonia 21.67 19.20 26 15013 37117 110537143
Femoral neck fracture 21.50 19.20 16 15023 12551 110561709
Underdose 21.23 19.20 34 15005 63520 110510740
Small intestinal haemorrhage 21.13 19.20 11 15028 4607 110569653
Lymphangiosis carcinomatosa 20.89 19.20 9 15030 2473 110571787
Therapeutic product effect decreased 20.79 19.20 4 15035 244312 110329948
Condition aggravated 20.78 19.20 43 14996 734793 109839467
Meningitis 20.25 19.20 15 15024 11687 110562573
Septic shock 20.25 19.20 57 14982 157471 110416789
Wheezing 20.05 19.20 5 15034 255225 110319035
Oesophagitis 19.95 19.20 22 15017 28693 110545567
Steroid diabetes 19.79 19.20 11 15028 5243 110569017
Large intestine perforation 19.56 19.20 17 15022 16612 110557648
Gastric antral vascular ectasia 19.49 19.20 7 15032 1190 110573070
Discomfort 19.39 19.20 3 15036 214704 110359556

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC A02BC08 ALIMENTARY TRACT AND METABOLISM
DRUGS FOR ACID RELATED DISORDERS
DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD)
Proton pump inhibitors
ATC A02BD14 ALIMENTARY TRACT AND METABOLISM
DRUGS FOR ACID RELATED DISORDERS
DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD)
Combinations for eradication of Helicobacter pylori
ATC A02BD15 ALIMENTARY TRACT AND METABOLISM
DRUGS FOR ACID RELATED DISORDERS
DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD)
Combinations for eradication of Helicobacter pylori
ATC A02BD17 ALIMENTARY TRACT AND METABOLISM
DRUGS FOR ACID RELATED DISORDERS
DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD)
Combinations for eradication of Helicobacter pylori
CHEBI has role CHEBI:33282 antibacterial agent
CHEBI has role CHEBI:49201 anti-ulcer drug

Related Drugs by ATC class:

A02BC Proton pump inhibitors 8 drugs
dexlansoprazoledexrabeprazoleesomeprazoleilaprazolelansoprazoleomeprazolepantoprazolerabeprazole
A02BD Combinations for eradication of Helicobacter pylori 13 drugs
amoxicillinbismuth subcitrateclarithromycinesomeprazolelansoprazolelevofloxacinmetronidazoleomeprazolepantoprazolerabeprazolerifabutintetracycline show all 13 →

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Erosive esophagitis indication 40719004
Duodenal ulcer disease indication 51868009 DOID:1724
Gastro-esophageal reflux disease with esophagitis indication 266433003
Gastric ulcer indication 397825006 DOID:10808
Infection caused by Helicobacter pylori indication 721730009
Rilpivirine-containing products contraindication 703123005




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 9.09 Basic
pKa2 2.72 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRouteExclusivity dateDescription
EQ 10MG BASE VOQUEZNA PHATHOM N215151 Nov. 1, 2023 RX TABLET ORAL Nov. 1, 2026 NEW PRODUCT
EQ 20MG BASE VOQUEZNA PHATHOM N215151 Nov. 1, 2023 RX TABLET ORAL Nov. 1, 2026 NEW PRODUCT
EQ 10MG BASE VOQUEZNA PHATHOM N215151 Nov. 1, 2023 RX TABLET ORAL May 3, 2027 NEW CHEMICAL ENTITY
EQ 20MG BASE VOQUEZNA PHATHOM N215151 Nov. 1, 2023 RX TABLET ORAL May 3, 2027 NEW CHEMICAL ENTITY
500MG;500MG;EQ 20MG BASE VOQUEZNA TRIPLE PAK PHATHOM N215152 May 3, 2022 RX CAPSULE, TABLET, TABLET ORAL May 3, 2027 NEW CHEMICAL ENTITY
500MG;EQ 20MG BASE VOQUEZNA DUAL PAK PHATHOM N215153 May 3, 2022 RX CAPSULE, TABLET ORAL May 3, 2027 NEW CHEMICAL ENTITY
EQ 10MG BASE VOQUEZNA PHATHOM N215151 Nov. 1, 2023 RX TABLET ORAL July 17, 2027 USE OF VONOPRAZAN FOR THE RELIEF OF HEARTBURN ASSOCIATED WITH NON-EROSIVE GASTROESOPHAGEAL REFLUX DISEASE IN ADULTS
EQ 10MG BASE VOQUEZNA PHATHOM N215151 Nov. 1, 2023 RX TABLET ORAL May 3, 2032 GENERATING ANTIBIOTIC INCENTIVES NOW
EQ 20MG BASE VOQUEZNA PHATHOM N215151 Nov. 1, 2023 RX TABLET ORAL May 3, 2032 GENERATING ANTIBIOTIC INCENTIVES NOW
500MG;500MG;EQ 20MG BASE VOQUEZNA TRIPLE PAK PHATHOM N215152 May 3, 2022 RX CAPSULE, TABLET, TABLET ORAL May 3, 2032 GENERATING ANTIBIOTIC INCENTIVES NOW
500MG;EQ 20MG BASE VOQUEZNA DUAL PAK PHATHOM N215153 May 3, 2022 RX CAPSULE, TABLET ORAL May 3, 2032 GENERATING ANTIBIOTIC INCENTIVES NOW

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Potassium-transporting ATPase Transporter INHIBITOR Ki 8 SCIENTIFIC LITERATURE SCIENTIFIC LITERATURE

External reference:

IDSource
1R5L3J156G UNII
D10466 KEGG_DRUG
881681-01-2 SECONDARY_CAS_RN
4041456 VANDF
C4080009 UMLSCUI
CHEBI:136048 CHEBI
HKT PDB_CHEM_ID
CHEMBL2079130 ChEMBL_ID
15981397 PUBCHEM_CID
DB11739 DRUGBANK_ID
CHEMBL2064032 ChEMBL_ID
9535 INN_ID
C552956 MESH_SUPPLEMENTAL_RECORD_UI
11549 IUPHAR_LIGAND_ID
2604576 RXNORM
40597 MMSL
40790 MMSL
d09874 MMSL
019050 NDDF
019051 NDDF
555661000221100 SNOMEDCT_US
555671000221109 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
VOQUEZNA HUMAN PRESCRIPTION DRUG LABEL 1 81520-100 TABLET 13.36 mg ORAL NDA 32 sections
VOQUEZNA HUMAN PRESCRIPTION DRUG LABEL 1 81520-200 TABLET 26.72 mg ORAL NDA 32 sections